وزارة الصحة
Ministry of Health
Sultanate of Oman سلطنة عمان

To:

Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahdha Hospital
Director General of Health Services in all Governorates
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Health Institutions)
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
The Head of Medical Services in University Medical City
The Head of Medical Services in Medical City for Military and Security Services
Director of Pharmacy of Qaboos Comprehensive Cancer Care & Research Center
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman
All Private Pharmacies & Drug Stores

After Compliments,

Kindly find attached our Circular No. 193 /2026 dated 11 /11/2026 Regarding the Warning about contaminated unauthorized injectable peptides and non-peptide drugs.

Copy to:

- **Director of Pharmacovigilance Department, DSC**
- **Director of Medicine Registration Department, DSC**
- **Director of Regulatory Compliance Department, DSC**
- **Director of Central Quality Control Lab., DSC**
- **Director of Medical Device Department, DSC**
- **Section Head of Medicine Safety Evaluation**
- **Section Head of Quality Problems and Medication Errors**
- **Section Head of Pharmacovigilance**
- **Section Head of Clinical Trials**

P.O. Box 393, Postal Code 100, Muscat, Sultanate of Oman, Tel: +968 22357628, +968 22357111, Email: dscpho@moh.gov.om

وزارة الصحة
Ministry of Health
Sultanate of Oman سلطنة عمان

Circular No. 113/2026
01 -06-1448
11 -11-2026

Subject: Alert about contaminated unauthorized injectable peptides and non peptide drugs

The Drug Safety Center (DSC) would like to share a public advisory issued by Health Canada regarding contaminated unauthorized injectable peptide and non-peptide drugs sold online by Shanghai ERP Peptide Biotechnology Co., Ltd. (ERP Peptide). Health Canada highlighted the following:

- **Laboratory findings:** Testing of seized products detected bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Propionibacterium (Cutibacterium) acnes.
- **Serious health risk:** Injection of contaminated products may cause serious infections requiring hospitalization and, in severe cases, life-threatening sepsis. People with a compromised immune system are at greater risk.
- Injectable products obtained online or from unverified sources, including those promoted for weight loss, muscle growth or anti-aging.
- **Regulatory status:** These unauthorized products have not been assessed by Health Canada for safety, efficacy or quality. They may contain incorrect amounts of active ingredients, undeclared substances or contaminants, and their sterility cannot be assured.
- **Affected Products:** Examples of unauthorized injectable peptide and non-peptide drugs sold online:
  - Human Chorionic Gonadotropin (hCG)
  - MOTS-C
  - NAD+
  - Retatrutide
  - Tesamorelin
  - Tirzepatide

Advice for Healthcare Professionals

- Do not prescribe, dispense or administer the unauthorized products described in this alert. Obtain medicinal products only from authorized and licensed suppliers.
- If a suspected product is identified, stop its use, and notify DSC. Retain the product, packaging, photographs, batch details and supplier information for investigation.
- Assess patients who have used these products. Arrange urgent medical evaluation and manage according to the clinical condition.

P.O. Box 393, Postal Code 100, Muscat, Sultanate of Oman, Tel: +968 22357628, +968 22357111, Email: dscpho@moh.gov.om

Advice for Patients

- Do not buy or use the unauthorized injectable products described in this alert. Do not inject products labelled "For Research Use Only – Not for Human Consumption". Obtain prescription medicines from licensed pharmacies and use them under the care of a licensed healthcare professional.
- If you have used a suspected product and develop fever, chills, redness, swelling or pain at the injection site, or feel unwell, seek immediate medical attention. Keep the product and packaging for investigation and inform your healthcare professional about the product and where it was obtained.

Call to Report

Healthcare professionals, patients and caregivers are requested to report suspected unauthorized products, quality problems and associated adverse events to the Pharmacovigilance Department at the Drug Safety Center through the established reporting channels. Include available product and batch details, source of supply, photographs, exposure information and clinical outcome.

Ph. Ibrahim Nasser Al Rashdi

Director General

P.O. Box 393, Postal Code 100, Muscat, Sultanate of Oman, Tel: +968 22357628, +968 22357111, Email: dscpho@moh.gov.om